Catalog No.
DHJ53401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Phosphatonin, FGF-23, HYPF, FGF23, Fibroblast growth factor 23, Tumor-derived hypophosphatemia-inducing factor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9GZV9
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
KRN-23, UX-023, CAS: 1610833-03-8
Clone ID
Burosumab
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial, PMID: 31104833
Burosumab Therapy in Children with X-Linked Hypophosphatemia, PMID: 29791829
Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children, PMID: 32547492
Burosumab, PMID: 31643797
Burosumab: First Global Approval, PMID: 29679282
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis, PMID: 29947083
Burosumab, PMID: 30000040
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period, PMID: 31165191
Burosumab for the Treatment of Tumor-Induced Osteomalacia, PMID: 33338281
Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease, PMID: 32701599
Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial, PMID: 31369697
Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia, PMID: 32967046
Pharmacoeconomic Review Report: Burosumab (Crysvita): Kyowa Kirin Limited [Internet], PMID: 33301277
Clinical Review Report: Burosumab (Crysvita): (Kyowa Kirin Limited) [Internet], PMID: 33347104
Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia, PMID: 31068690
Burosumab for Pediatric X-Linked Hypophosphatemia, PMID: 33970403
Burosumab in X-linked hypophosphatemia: a profile of its use in the USA, PMID: 30459508
Burosumab in tumor-induced osteomalacia: A case report, PMID: 31382017
An Overview of Rickets in Children, PMID: 32647755
CADTH Canadian Drug Expert Committee Recommendation: Burosumab (Crysvita — Kyowa Kirin Limited): Indication: Treatment of X-linked hypophosphatemia [Internet], PMID: 33301278
Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia, PMID: 32133333
Approach to patients with hypophosphataemia, PMID: 31924563
Burosumab treatment of children with X-linked hypophosphataemic rickets, PMID: 31104830
Tumour-induced osteomalacia, PMID: 28703220
Tumor-Induced Osteomalacia, PMID: 32504138
Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD, PMID: 31171590
FGF23, Hypophosphatemia, and Emerging Treatments, PMID: 31485552
X-Linked Hypophosphatemia: A New Era in Management, PMID: 33204932
Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations, PMID: 33112809
Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia, PMID: 29989668
Management of X-linked hypophosphatemia in adults, PMID: 31863781
Antibodies to watch in 2019, PMID: 30516432
FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference, PMID: 32653872
Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia, PMID: 31930323
Burosumab treatment for fibrous dysplasia, PMID: 33984553
Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH), PMID: 30928313
Burosumab: A new drug to treat hypophosphatemic rickets, PMID: 29545670
Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial, PMID: 30638856
Effects of burosumab on osteocalcin and bone mineral density in patient with 15-year history of nonremission tumor-induced osteomalacia initially treated with conventional therapy: Case report, PMID: 33294501
New Therapies for Hypophosphatemia-Related to FGF23 Excess, PMID: 32504139
The evolving therapeutic landscape of genetic skeletal disorders, PMID: 31888683
FGF23 and Associated Disorders of Phosphate Wasting, PMID: 31599133
FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment, PMID: 33295878
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia, PMID: 33484279
First-in-Asian Phase I Study of the Anti-Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X-linked Hypophosphatemia, PMID: 30828689
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment, PMID: 29381780
Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA, PMID: 31186611
Burosumab for Tumor-Induced Osteomalacia: Not Enough of a Good Thing, PMID: 33950530
Diagnosis and management of pediatric metabolic bone diseases associated with skeletal fragility, PMID: 32692054
Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia, PMID: 34352114
For research use only. Not for human or drug use.
